The application for authorisation referred to in Article L. 1161-5 is sent by the company exploiting the medicinal product to the Director General of the Agence nationale de sécurité du médicament et des produits de santé. It shall mention :
1° The name and address of the applicant for authorisation and, where applicable, those of the marketing authorisation holder ;
2° The name of the medicinal product, including its international non-proprietary name, and the name of the programme.